Morgan Stanley Recursion Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 5,010,433 shares of RXRX stock, worth $20.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,010,433

Previous 2,860,527 75.16%

Holding current value

$20.9 Million

Previous $19.3 Million 37.07%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$5.29 - $10.87 $11.4 Million - $23.4 Million	2,149,906 Added 75.16%	5,010,433 $26.5 Million
Q4 2024 Feb 14, 2025	BUY	$5.7 - $8.27 $5.6 Million - $8.13 Million	983,326 Added 52.38%	2,860,527 $19.3 Million
Q3 2024 May 14, 2025	BUY	$5.92 - $8.6 $644,622 - $936,445	108,889 Added 6.16%	1,877,201 $12.4 Million
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $644,622 - $936,445	108,889 Added 6.16%	1,877,201 $12.4 Million
Q2 2024 May 14, 2025	SELL	$7.35 - $10.05 $8.03 Million - $11 Million	-1,092,215 Reduced 38.18%	1,768,312 $13.3 Million
Q2 2024 Oct 17, 2024	SELL	$7.35 - $10.05 $1.44 Million - $1.96 Million	-195,465 Reduced 9.95%	1,768,312 $13.3 Million
Q2 2024 Aug 14, 2024	SELL	$7.35 - $10.05 $1.44 Million - $1.96 Million	-195,465 Reduced 9.95%	1,768,312 $13.3 Million
Q1 2024 Oct 17, 2024	BUY	$9.13 - $15.52 $1.78 Million - $3.03 Million	195,465 Added 11.05%	1,963,777 $19.6 Million
Q1 2024 Aug 16, 2024	SELL	$9.13 - $15.52 $5.59 Million - $9.5 Million	-612,122 Reduced 23.76%	1,963,777 $19.6 Million
Q1 2024 May 15, 2024	SELL	$9.13 - $15.52 $5.59 Million - $9.5 Million	-612,122 Reduced 23.76%	1,963,777 $19.6 Million
Q4 2023 Aug 16, 2024	BUY	$5.09 - $10.79 $4.11 Million - $8.71 Million	807,587 Added 45.67%	2,575,899 $25.4 Million
Q4 2023 Feb 13, 2024	BUY	$5.09 - $10.79 $9.01 Million - $19.1 Million	1,769,277 Added 219.34%	2,575,899 $25.4 Million
Q3 2023 Nov 15, 2023	BUY	$6.59 - $15.86 $2.74 Million - $6.6 Million	416,393 Added 106.7%	806,622 $6.17 Million
Q2 2023 Aug 14, 2023	BUY	$4.56 - $9.94 $596,730 - $1.3 Million	130,862 Added 50.45%	390,229 $2.92 Million
Q1 2023 May 15, 2023	SELL	$6.42 - $9.64 $473,821 - $711,470	-73,804 Reduced 22.15%	259,367 $1.73 Million
Q4 2022 Feb 14, 2023	BUY	$7.16 - $12.7 $409,759 - $726,808	57,229 Added 20.74%	333,171 $2.57 Million
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $424,683 - $737,636	54,238 Added 24.46%	275,942 $2.94 Million
Q2 2022 Oct 27, 2022	BUY	$5.04 - $9.26 $408,779 - $751,050	81,107 Added 57.69%	221,704 $1.81 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.26 $408,779 - $751,050	81,107 Added 57.69%	221,704 $1.81 Million
Q1 2022 Oct 27, 2022	SELL	$6.16 - $18.03 $499,619 - $1.46 Million	-81,107 Reduced 36.58%	140,597 $1.01 Million
Q1 2022 May 13, 2022	BUY	$6.16 - $18.03 $154,591 - $452,480	25,096 Added 21.73%	140,597 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$16.14 - $21.86 $1.71 Million - $2.31 Million	105,801 Added 1090.73%	115,501 $1.98 Million
Q3 2021 Nov 15, 2021	BUY	$19.03 - $41.33 $184,591 - $400,901	9,700 New	9,700 $223,000

Others Institutions Holding RXRX

# of Institutions

365

Shares Held

286M

Call Options Held

3.28M

Put Options Held

3.16M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $754M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account